Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.
Giulia Corradetti, MD
Advertisement
Giulia Corradetti, MD, is a research scientist at Doheny Eye Institute.
Articles by Giulia Corradetti, MD
At the Envision Summit 2025 in San Juan, Puerto Rico, Giulia Corradetti, MD discussed AI applications in the identification and prediction of OCT structural biomarkers in intermediate AMD.
Advertisement
Latest Updated Articles
Envision Summit 2025: Prediction of structural OCT biomarkers in intermediate AMD using deep learningPublished: February 20th 2025 | Updated:
ARVO 2025: Post-hoc analysis on GATHER 2 clinical trial dataPublished: May 14th 2025 | Updated:
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
2
Ophthalmic innovation by the decades: The 2010s
3
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
4
AAO 2025: Arshad M. Khanani, MD, highlights 3-year results from the GATHER2 open-label extension trial
5
.png "Optometry Times"){kind=logo}
